Company News & Events

Oryzon gets its first Patent in the US

3 June 2013

Oryzon announced today that it has received the Notice of allowance of its first patent covering LSD1 inhibitors.

Barcelona - Oryzon has received from the US Patent and Trademark Office (USPTO) the Notice of allowance for its patent application US13/066,616 (published as US 2011/0263604) covering covalent inhibitors of Lysine Specific Demethylase-1 (LSD1, aka KDM1A). This is the first patent to be granted from a broad portfolio in LSD1 inhibitors that includes 18 patent families and that gives Oryzon a dominant IP position in this area of Epigenetics drugs.

Click here to see full Press Release.

Share this story